Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PHIO

Phio Pharmaceuticals Corp

Dec 06 • 04:00PM ET

2.84

Dollar change +0.13
Percentage change 4.80	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT MRNA ARWR ALNY IONS SRPT VNDA RNA SGMO

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.94	Insider Own	3.74%	Shs Outstand	1.06M	Perf Week	4.41%
Market Cap	3.14M	Forward P/E	-	EPS next Y	-	Insider Trans	5.34%	Shs Float	1.02M	Perf Month	-12.88%
Income	-7.42M	PEG	-	EPS next Q	-	Inst Own	2.70%	Short Float	4.70%	Perf Quarter	2.53%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	66.12%	Short Ratio	0.69	Perf Half Y	-57.64%
Book/sh	5.16	P/B	0.55	EPS next Y	-	ROA	-96.33%	Short Interest	0.05M	Perf Year	-80.15%
Cash/sh	4.87	P/C	0.58	EPS next 5Y	-	ROE	-122.03%	52W Range	2.17 - 18.81	Perf YTD	-58.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	62.38%	ROI	-150.00%	52W High	-84.90%	Beta	1.46
Dividend TTM	-	Quick Ratio	6.38	Sales past 5Y	-36.96%	Gross Margin	-	52W Low	31.01%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	6.38	EPS Y/Y TTM	81.03%	Oper. Margin	-	RSI (14)	52.67	Volatility	9.03% 10.53%
Employees	9	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	36.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	84.99%	Payout	-	Rel Volume	0.48	Prev Close	2.71
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 19 AMC	Avg Volume	69.40K	Price	2.84
SMA20	9.81%	SMA50	-0.85%	SMA200	-42.10%	Trades		Volume	33,582	Change	4.80%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-20	Initiated	H.C. Wainwright	Buy	$4

Dec-03-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Nov-19-24 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study (Newsfile) +12.42%
Nov-14-24 05:47PM	Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Newsfile) -5.11%
Nov-07-24 10:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Nov-01-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
08:00AM	Loading…
Oct-24-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Oct-18-24 01:30PM	Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +9.81%
08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series (Newsfile)
Oct-16-24 08:00AM	Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference (Newsfile) +17.75%
Oct-07-24 08:00AM	Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells (Newsfile) -6.17%
Oct-02-24 04:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -6.47%
Oct-01-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference (Newsfile)
Sep-25-24 08:00AM	INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society (Newsfile)
Sep-17-24 08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +11.64%
Sep-16-24 08:00AM	Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA (Newsfile)
07:00AM	Loading…
Sep-09-24 07:00AM	Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Newsfile) +6.13%
Aug-29-24 08:30AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -7.37%
Aug-14-24 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Newsfile)
Aug-06-24 08:00AM	Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound (Newsfile)
Aug-01-24 08:00AM	Phio Pharmaceuticals Announces New Chief Financial Officer (Newsfile) -7.34%
Jul-12-24 08:00AM	Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds (Newsfile) -13.60%
Jul-08-24 08:00AM	Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 (Newsfile) +9.06%
Jul-05-24 08:00AM	Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds (Newsfile)
Jul-02-24 11:45AM	Phio Pharmaceuticals Announces Reverse Stock Split (Newsfile) -9.17%
Jun-18-24 07:30AM	Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging (Newsfile)
May-28-24 07:30AM	Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762 (Newsfile)
May-23-24 05:00PM	Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (Newsfile)
May-17-24 09:00AM	Phio Pharmaceuticals Secures New Investor (GlobeNewswire) +7.44%
May-16-24 08:00AM	Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) (GlobeNewswire) -8.45%
May-15-24 01:00PM	Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study (GlobeNewswire) +9.02%
11:53PM	Loading…
May-09-24 11:53PM	PHIO Stock Earnings: Phio Pharma Reported Results for Q1 2024 (InvestorPlace) -8.51%
05:25PM	Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update (GlobeNewswire)
Apr-30-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) (GlobeNewswire)
Apr-22-24 01:10PM	Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells (GlobeNewswire) +29.69%
Apr-16-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) (GlobeNewswire)
Apr-11-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) (GlobeNewswire)
Apr-03-24 07:30AM	National Spotlight Features Phio's Innovative RNAi Technology Platform (GlobeNewswire)
Apr-02-24 07:30AM	Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-24 07:30AM	Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire) -21.50%
Mar-13-24 02:00PM	Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research (GlobeNewswire)
Mar-06-24 10:30AM	Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders (GlobeNewswire) +6.63%
Jan-31-24 08:00AM	Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire)
Dec-07-23 08:00AM	Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds (GlobeNewswire) -42.14%
Nov-09-23 04:30PM	Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -10.53% +5.88%
07:30AM	Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas (GlobeNewswire)
Nov-03-23 12:00PM	Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control (GlobeNewswire) +6.57%
Oct-12-23 11:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -32.31%
Oct-11-23 07:30AM	Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894 (GlobeNewswire) +87.05%
Sep-06-23 07:30AM	Phio CEO to Speak at Wainwright Conference in New York in September (GlobeNewswire)
Aug-21-23 07:30AM	Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute (GlobeNewswire)
Aug-10-23 04:30PM	Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-02-23 01:30PM	Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire)
May-31-23 08:00AM	Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) -13.15%
May-24-23 07:30AM	Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute (PR Newswire)
May-18-23 12:00PM	Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells (PR Newswire) +34.31%
May-16-23 07:30AM	Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas (PR Newswire) +21.36%
May-11-23 05:00PM	Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -10.14%
Apr-20-23 02:20PM	Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Apr-18-23 12:10PM	Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -19.24%
07:30AM	Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL (PR Newswire)
Apr-17-23 07:30AM	Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity (PR Newswire) +18.48%
Mar-22-23 05:05PM	Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update (PR Newswire) +8.22%
Feb-22-23 07:30AM	Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer (PR Newswire)
Feb-13-23 07:30AM	Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
Feb-10-23 07:30AM	Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification (PR Newswire) -11.68%
Jan-25-23 08:30AM	Phio Pharmaceuticals Announces Reverse Stock Split (PR Newswire) -6.45%
Jan-06-23 04:30PM	Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco (PR Newswire) +40.26%
01:30PM	Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors (PR Newswire)
Dec-21-22 04:15PM	Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma (PR Newswire)
Nov-10-22 06:25PM	Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.13% -11.07%
05:05PM	Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
09:00AM	Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th (PR Newswire)
Oct-25-22 12:00PM	What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock (Zacks)
Oct-12-22 09:38AM	Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS (Zacks) +9.19%
Oct-07-22 05:42PM	Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia (Zacks)
Oct-06-22 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (PR Newswire)
Sep-29-22 08:30AM	Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman (PR Newswire) -5.20%
Sep-27-22 03:51PM	Encompass Health (EHC) Plans Hospital to Aid Florida Footprint (Zacks)
Sep-26-22 12:09PM	Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug (Zacks)
Sep-22-22 07:30AM	Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference (PR Newswire)
Sep-12-22 07:30AM	Phio Pharmaceuticals Announces Acceptance of Six Abstracts at The 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (PR Newswire)
Aug-11-22 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
Jul-11-22 06:53AM	Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Is About To Turn The Corner (Simply Wall St.)
Jun-06-22 02:15PM	Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting (PR Newswire)
May-16-22 12:22PM	Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells (Benzinga)
08:00AM	Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity of HER2-CAR-T Cells at ASGCT 2022 (PR Newswire)
May-12-22 04:50PM	Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
May-05-22 08:33AM	Phio Pharmaceuticals Announces Senior Leadership Personnel Change (PR Newswire)
May-03-22 07:30AM	Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022 (PR Newswire)
May-02-22 04:30PM	Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022 (PR Newswire)
07:30AM	Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors (PR Newswire)
Apr-26-22 10:15AM	Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma (PR Newswire) -8.77%
Apr-18-22 09:30AM	Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer (PR Newswire)
Apr-11-22 03:39PM	We're Keeping An Eye On Phio Pharmaceuticals' (NASDAQ:PHIO) Cash Burn Rate (Simply Wall St.) -25.53%
10:41AM	Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism (GlobeNewswire)
Apr-08-22 01:00PM	Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022 (PR Newswire) +159.18%
Mar-22-22 05:00PM	Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update (PR Newswire)
Mar-08-22 04:30PM	Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022 (PR Newswire) +5.71%
Feb-22-22 09:30AM	Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2 (PR Newswire)
Jan-11-22 12:30PM	3 Hot Penny Stocks: Why TLOFF, PHIO and SBEV Are Seeing Big Gains Today (InvestorPlace) +8.41%

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bitterman Robert J	President & CEO	Jun 07 '24	Buy	0.74	1,000	740	20,990	Jun 11 05:00 PM
Bitterman Robert J	President & CEO	Jun 06 '24	Buy	0.75	1,000	750	19,990	Jun 10 05:00 PM
Bitterman Robert J	President & CEO	Feb 26 '24	Buy	0.91	2,500	2,275	18,990	Feb 27 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHIO

Phio Pharmaceuticals Corp

Upgrade your FINVIZ experience